scholarly journals Three-Year Disease-Free Survival After D2 Dissection and Liver Metastasectomy in a Gastric Cancer Case with Poor Prognostic Factors: A Case Report

2017 ◽  
Vol 3 (1) ◽  
Author(s):  
Aydın AYTEKİN ◽  
Süleyman ŞAHİN ◽  
Muhammet Bekir HACIOĞLU ◽  
Fatih KARATAŞ ◽  
Mustafa ALTINBAŞ
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Case Report ◽  
Disease Free Survival ◽  
Cancer Case ◽  
Gastric Cancer Case ◽  
Free Survival ◽  
D2 Dissection ◽  
Disease Free

The impact of indoleamine 2,3-dioxygenase (IDO) expression on stage III gastric cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 75-75
Author(s):  
Hideya Kashihara ◽  
Mitsuo Shimada ◽  
Kozo Yoshikawa ◽  
Jun Higashijima ◽  
Takuya Tokunaga ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Disease Free Survival ◽  
Stage Iii ◽  
Clinicopathological Factors ◽  
Negative Group ◽  
Free Survival ◽  
Positive Group ◽  
Group 3 ◽  
Disease Free

75 Background: Indoleamine 2,3-dioxygenase (IDO) downregulates T cell activation and is related to immune tolerance. The aim of this study was to clarify the significance of IDO expression and to analyze the relationships among the expression of IDO, TGF-b, and Foxp3 in gastric cancer (GC). Methods: Sixty patients who underwent curative gastrectomy for stage III gastric cancer were included in this study. The expressions of IDO, TGF-b, and Foxp3 were examined by immunohistochemistry. The patients were divided into two groups: the IDO-positive group (n = 23) and negative group (n = 37). Clinicopathological factors were compared between the two groups. Univariate analysis was used to assess overall (OS) and disease-free survival (DFS) in several prognostic factors. Multivariate analysis was used to identify the independent prognostic factors. Results: IDO expression was not positively correlated with any clinicopathological factors. IDO expression was positively correlated with TGF-b expression (p < 0.05) and TGF-b expression was positively correlated with FoxP3 expression (p < 0.05). Overall survival (OS) rates were significantly poorer in the IDO-positive group compared with the IDO-negative group (3-year OS, 78.5% vs. 90%, respectively; p < 0.05). Multivariate analysis identified IDO expression as independent prognostic factors in OS. Disease-free survival (DFS) was significantly poorer in the IDO-positive group compared with the IDO-negative group (3-year DFS, 59.3% vs. 69.3%, respectively; p < 0.05). Conclusions: IDO is associated with poor prognosis and immuno-tolerance through Treg in Stage III GC.

scholarly journals Evaluation of Prognostic Factors Affecting Disease-Free Survival and Overall Survival in Patients with Operated Gastric Cancer Treated with Adjuvant Treatment

2020 ◽  
Vol 53 (2) ◽  
pp. 194-203
Author(s):  
İrem Bilgetekin ◽  
Cengiz Karaçin ◽  
Fatma Buğdaycı Başal ◽  
Umut Demirci ◽  
Ömür Berna Öksüzoğlu
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Adjuvant Treatment ◽  
Disease Free Survival ◽  
Free Survival ◽  
Factors Affecting ◽  
Disease Free

scholarly journals Choroid Plexus Metastasis from Gastric Cancer —Case Report—

1994 ◽  
Vol 34 (3) ◽  
pp. 183-186 ◽  
Author(s):  
Hiromichi NAKABAYASHI ◽  
Keiji MURATA ◽  
Masakazu SAKAGUCHI ◽  
Kazuhiro NAKAJIMA ◽  
Junsuke KATSUYAMA
Keyword(s):  
Gastric Cancer ◽  
Case Report ◽  
Choroid Plexus ◽  
Cancer Case ◽  
Gastric Cancer Case

Overexpression of NUAK1 is associated with disease-free survival and overall survival in patients with gastric cancer

2014 ◽  
Vol 31 (7) ◽  
Author(s):  
Xiao-tian Ye ◽  
Ai-jun Guo ◽  
Peng-fei Yin ◽  
Xian-dong Cao ◽  
Jia-cong Chang
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Disease Free Survival ◽  
Free Survival ◽  
Disease Free

scholarly journals Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy

2020 ◽  
Vol 59 (7) ◽  
pp. 809-817
Author(s):  
Marloes Duijm ◽  
Noëlle C. van der Voort van Zyp ◽  
Patrick V. Granton ◽  
Paul van de Vaart ◽  
Mirjam E. Mast ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Prognostic Factors ◽  
Local Control ◽  
Stereotactic Body Radiation Therapy ◽  
Disease Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Survival ◽  
Disease Free

scholarly journals Determination of prognostic factors of surgically treated pathological Stage IIIA non-small cell lung cancer

2020 ◽  
Vol 28 (3) ◽  
pp. 496-504
Author(s):  
Muhammet Sayan
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Disease Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Survival ◽  
Disease Free

Background: This study aims to identify the prognostic factors in Stage IIIA non-small cell lung cancer and to investigate whether there was a significant difference in terms of overall survival and disease-free survival among the subgroups belonging to this disease stage. Methods: Between January 2010 and December 2018, a total of 144 patients (125 males, 19 females; median age 60 years; range, 41 to 80 years) who were operated for non-small cell lung cancer in our clinic and whose pathological stage was reported as IIIA were retrospectively analyzed. Data including demographic and clinical characteristics of the patients, histopathological diagnosis, the standardized uptake value of the mass on positron emission tomography-computed tomography, tumor diameter, type of surgery, lymph node metastasis status, visceral pleural invasion, and overall and disease-free survival rates were recorded. Results: The median survival was 39 (range, 27.8 to 46.1) months and the five-year overall survival rate was 28%. The mean tumor diameter was 4.3±2.7 cm. The median disease-free survival was 37 (range, 28.1 to 48.6) months and the five-year disease-free survival rate was 26.9%. In the multivariate analysis, overall survival and disease-free survival in T2N2M0 subgroup were significantly worse than the other subgroups. The other poor prognostic factors of survival were the standardized uptake value of the tumor, pneumonectomy, and histopathological subtypes other than squamous cell carcinoma and adenocarcinoma. Parietal pleural invasion was significantly associated with worse disease-free survival rates. Conclusion: Our results showed that there may be significant survival differences between subgroups created by tumor histopathology, lymph node invasion and the type of surgery in a heterogeneous lung cancer stage.

Value of Preoperative Inflammation-Based Prognostic Scores in Predicting Overall Survival and Disease-Free Survival in Patients with Gastric Cancer

2014 ◽  
Vol 21 (6) ◽  
pp. 1998-2004 ◽  
Author(s):  
Paolo Aurello ◽  
Simone Maria Tierno ◽  
Giammauro Berardi ◽  
Federico Tomassini ◽  
Paolo Magistri ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Disease Free Survival ◽  
Prognostic Scores ◽  
Free Survival ◽  
Disease Free

A prospective, randomized, controlled, multicenter study of apatinib combined with S-1 plus docetaxel as adjuvant therapy for locally advanced gastric cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16019-e16019
Author(s):  
Zhili Shan ◽  
Feng Guo ◽  
Hong Chen ◽  
Dapeng Li ◽  
Zhongqi Mao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Free Survival ◽  
Randomized Controlled ◽  
Locally Advanced Gastric Cancer ◽  
Group A ◽  
Group B ◽  
Disease Free

e16019 Background: Postoperative adjuvant chemotherapy is commonly given after the curative resection of gastric cancer (GC) in both Eastern and Western countries. Several studies have investigated the feasibility and safety of S-1 plus docetaxel or S-1 plus cisplatin. However, the best choice of adjuvant treatment for patients with gastric cancer is still debated. Apatinib, an oral small molecular of VEGFR-2 TKI, has been confirmed to improve OS and PFS with acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. In this study, we aimed to evaluate the efficacy and safety of apatinib combined with S-1/docetaxel for locally advanced gastric cancer (T3-4aN+M0). Methods: This is a prospective, randomized, controlled, multicenter clinical study. Patients with locally advanced gastric cancer, pathological stage T3-4aN+M0 who underwent D2 lymphadenectomy without prior anti-cancer therapy were included. All these patients were assigned to group A or B. Patients in group A received 6 cycles (21 days a cycle) of adjuvant therapy using S-1 (80-120mg/d, d1-14), and docetaxel (40mg/m2, d1). Group B received the same regimen with the addition of apatinib (250mg, qd.). The primary endpoint was disease-free survival (DFS). The final analysis cutoff date was 30 November, 2020. Results: A total of 45 patients were enrolled from January 2019 to November, 2010 and assigned to group A (21) or group B (24). The DFS was not reached in both of the groups. The 1-year disease-free survival rate was 60% in group A and 90% in the group B, while the difference was not significant. The main AEs in group A were anemia (55%), nausea (50%) and neutropenia (40%); The most common AEs in group B were anemia (45%) neutropenia (40%) and diarrhea (25%). There were no treatment-related deaths. The longest administered time of apatinib with no progression was 457 days. And the median time to receive apatinib was 329 days. Conclusions: Combination of apatinib with S-1/docexal chemotherapy shows clinical benefits in locally advanced gastric cancer (T3-4aN+M0), with tolerable toxicity. The study is still ongoing to reach our final endpoint, DFS. Clinical trial information: ChiCTR2000038900.

scholarly journals Prognostic Factors of Disease-Free Survival in Vulvar Cancer Patients

2014 ◽  
Vol 25 ◽  
pp. iv323
Author(s):  
Y. Poryvaev ◽  
G.A. Nerodo ◽  
V. Ivanova ◽  
E. Nerodo
Keyword(s):  
Prognostic Factors ◽  
Cancer Patients ◽  
Vulvar Cancer ◽  
Disease Free Survival ◽  
Free Survival ◽  
Disease Free
Sign in / Sign up

Export Citation Format

Share Document